Canaccord lowered the firm’s price target on Nevro to $19 from $23 and keeps a Hold rating on the shares. The firm updated its model following the release of its preliminary Q4 and 2023 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVRO:
- Nevro announces Carelon publication on new interventional pain management policy
- Nevro downgraded to Sector Perform from Outperform at RBC Capital
- Nevro announces restructuring plan, 5% workforce reduction
- Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
- Nevro sees FY23 revenue $425M, consensus $418.33M
